Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 22, 2025 11:20 ET | Source: Biogen Inc.

The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS

Long-term data published in JAMA Neurology further illustrate the effects of Biogen’s QALSODY on function, strength, and survival in SOD1-ALSOver 3 years, a subset of QALSODY-treated participants...
December 18, 2025 07:02 ET | Source: Athira Pharma, Inc.

Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million

Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing...
December 10, 2025 09:00 ET | Source: Muscular Dystrophy Association

Muscular Dystrophy Association Announces More Than $2.7 Million For Research Grants to Advance Breakthroughs Across Neuromuscular Diseases

New York, Dec. 10, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced more than $2.7 million in new research grants to advance groundbreaking discoveries across...
December 04, 2025 08:00 ET | Source: BTT Medical Institute

BTT Medical Institute Announces Unprecedented Case of Total Reversal of ALS through Re-engineering of the Nobel Prize-Winning Fever Therapy into a Brain-Guided, Artificial Intelligence-Controlled ThermoFebrile Treatment

MIAMI, Dec. 04, 2025 (GLOBE NEWSWIRE) -- BTT Medical Institute, in collaboration with btt Corp. (Brain Tunnelgenix Technologies Corp.), a medical technology company pioneering brain thermodynamics...
December 01, 2025 09:00 ET | Source: Muscular Dystrophy Association

In Honor of His Mother Helen, Beauty Expert Ken Paves Partners with the Muscular Dystrophy Association to Raise $5 Million for ALS Fund

New York, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced the launch of The Helen Paves Fund for Care and a Cure, an endowed fund created in collaboration...
November 25, 2025 08:30 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Nasal Foralumab Phase 2 Clinical Trial Accepted into Healey ALS MyMatch Program

BOSTON, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies, today...
November 25, 2025 07:00 ET | Source: Pasithea

Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS

-- The ALS Association is the world's leading funder of amyotrophic lateral sclerosis (ALS) research -- -- The Hoffman ALS Clinical Trial Awards Program was created to fund early- to mid-stage...
November 20, 2025 09:00 ET | Source: Muscular Dystrophy Association

NFL Players Lace Up for Muscular Dystrophy Association’s Mission in 2025 ‘My Cause My Cleats’ Campaign for Giving Tuesday

New York, Nov. 20, 2025 (GLOBE NEWSWIRE) -- This NFL season, during games in Weeks 12 and 13, hundreds of NFL players will step onto the field in custom-designed cleats as part of the 10th annual My...
November 12, 2025 09:00 ET | Source: Muscular Dystrophy Association

Muscular Dystrophy Association Names Sharon Hesterlee, PhD, as President and Chief Executive Officer

New York, Nov. 12, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) today announced the appointment of Sharon Hesterlee, PhD as President and Chief Executive Officer. Dr. Hesterlee...
November 11, 2025 09:00 ET | Source: Gnome Sciences

Gnome Sciences Announces Cancer Drug Shows Promise in Stopping Progression of ALS

Gnome Sciences Discovers Cancer Drug Shows Promise in Stopping Progression of ALS. BCL2 inhibitors such as venetoclax may treat neurodegenerative diseases